Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial

Nash

Nash is a decentralized finance (DeFi) platform designed to provide secure, non-custodial trading, payment, and investment services for digital assets. Founded in 2019, it leverages blockchain technology to allow users to maintain control of their funds while accessing advanced financial tools. Nash aims to bridge traditional finance and cryptocurrency markets through its integrated suite of services.

CBG: The 'Mother Cannabinoid' May Hold Key To Treating Nonalcoholic Fatty Liver Disease Symptoms
CBG: The 'Mother Cannabinoid' May Hold Key To Treating Nonalcoholic Fatty Liver Disease Symptoms
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings
Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings

Nash Recent News

Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment
Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment
Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients
Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform
Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform
NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study
NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies.
Exclusive: Axcella Health Aims To Become The Standard Of Care
Exclusive: Axcella Health Aims To Become The Standard Of Care
Axcella Health Inc (NASDAQ: AXLA) is a clinical-stage biotechnology company focused on endogenous metabolic modulators, or EEMs, said Axcella Health CEO Bill Hinshaw Thursday on Benzinga's YouTube show "Power Hour."<
89bio&#39;s NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference
89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference
89bio Inc (NASDAQ: ETNB) 
IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. 
Why Shares Of NASH Biotech Intercept Pharma Are Slumping
Why Shares Of NASH Biotech Intercept Pharma Are Slumping
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares were retreating sharply Monday on the back of an FDA rejection of its lead non-alcoholic steatohepatitis drug.
Diverging NASH Stories: CymaBay On Track To Restart, GenFit&#39;s Drug Flunks Late-Stage Study
Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study
Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge. 
NGM Biopharma Shares Spike Higher On Positive NASH Study Results
NGM Biopharma Shares Spike Higher On Positive NASH Study Results
ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment
Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment
Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
Analyst: Intercept&#39;s NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Lipocine&#39;s NASH Candidate Shows Promise In Liver Fat Study
Lipocine's NASH Candidate Shows Promise In Liver Fat Study
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved